Floatz logo

Bmn 255

Kidney Stone

BioMarin PharmaceuticalPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

4 Active assets in the Kidney Stone cohort.

Asset / SponsorPhaseRating
POTASSIUM CITRATE
National Center for Research Resources (NCRR)
Phase 3BB
POTASSIUM PHOSPHATE
National Center for Research Resources (NCRR)
Phase 3BB
LIDOCAINE
Hans Bahlmann
Phase 3B
NEPENTHE
Hans Bahlmann
Phase 3B
(±)-1-BUTYL-2',6'-PIPECOLOXYLIDIDE MONOHYDROCHLORIDE
Hans Bahlmann
Phase 3B
Ketorolac Tromethamine
Hamilton Health Sciences Corporation
Phase 3NR

Same molecule, other indications

Bmn 255 is also rated in:

metabolic dysfunction-associated steatotic liver diseaseDormant
CC
Indicative ·
43 / 100
View asset →
primary hyperoxaluriaDormant
NR
Indicative ·
/ 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →